# Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provides-business-update
Ticker: ROIV
Company: Roivant
Source: Roivant
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.roivant.com
## Summary

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

## Article Body
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026
## Recent Company News
- 2026-06-25 13:46 EST — [Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update](https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provides-business-update) — Source: Roivant
- 2026-06-25 13:46 EST — [Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Roivant
- 2026-06-25 13:46 EST — [Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update](https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-second-quarter-ended-september-30-2025-and-provides-business-update) — Source: Roivant
- 2026-06-25 13:46 EST — [Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day](https://biopharmsignal.com/news/ROIV/roivant-highlights-continued-pipeline-progress-and-outlook-for-company-s-next-phase-of-growth-at-2025-investor-day) — Source: Roivant
- 2026-06-25 13:46 EST — [Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026](https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026) — Source: Roivant
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)